Masako Yamaji

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years

W. Gruber, S. Irie, M. Shiramoto, 2014, Human vaccines & immunotherapeutics.

Immunogenicity and Safety of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan

W. Gruber, D. Scott, T. Togashi, 2013, The Pediatric infectious disease journal.

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan

A. Gurtman, W. Gruber, D. Scott, 2015, The Pediatric infectious disease journal.

A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults.

K. Jansen, W. Gruber, C. Knirsch, 2019, Vaccine.

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults

P. Dormitzer, S. Lockhart, U. Şahin, 2021, Nature Communications.

A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.

W. Gruber, M. Haranaka, D. Scott, 2024, Vaccine.

A Phase 3 Randomized Study to Evaluate Safety and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants.

W. Gruber, W. Watson, P. Giardina, 2024, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.